Beauregard Health System first in Southwest Louisiana to Offer New Sepsis Detection Technology
Contact: Sylvia Smith
Beauregard Health System first in Southwest Louisiana to Offer New Sepsis Detection Technology
IntelliSep® helps clinicians recognize sepsis earlier, providing test results in around 8 minutes
SAN FRANCISCO AND DERIDDER – February 3, 2026 – Cytovale®, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced that Beauregard Health System is now offering patients IntelliSep®, an FDA-approved diagnostic test for the early detection of sepsis, making the hospital the first in Southwest Louisiana to offer this advanced technology.
Sepsis is the leading cause of death in U.S. hospitals, with more than one-third of all in-hospital deaths attributed to the condition. About 80% of sepsis patients present to the ED, where it can be difficult to discern from ordinary infections or other conditions that can mimic sepsis.
“Sepsis can affect anyone, and early detection is critical—especially in a rural community,” said Dave Rupf, RN, Emergency Department Director at Beauregard Health System. “By bringing IntelliSep to Beauregard Health System, we’re pairing innovation with our commitment to caring for our neighbors close to home. This technology delivers objective results in about eight minutes, helping our clinicians act faster and with confidence. Being the first hospital in Southwest Louisiana to offer IntelliSep reflects our dedication to advancing care and improving outcomes for the community we serve.”
A New Approach to Sepsis Detection
IntelliSep, developed by Cytovale, is the first of its kind U.S. Food and Drug Administration (FDA)-cleared rapid diagnostic for sepsis indicated for use in the Emergency Department (ED). Now, adult patients who seek care in the ED at Beauregard Health System and present with signs or symptoms of an infection will be screened with IntelliSep.
What sets IntelliSep apart from other tools for sepsis detection, is that it arms clinicians with a new, objective measure of a patient’s immune system response. IntelliSep examines blood samples taken from patients as they enter the ED to see if the immune system is responding to an infection in a way that would indicate a septic or non-septic patient. In around 8 minutes, the test provides results that can empower clinicians to guide potentially septic patients to the appropriate care pathway. IntelliSep has been clinically validated to detect sepsis and has been shown to significantly reduce length of stay in the ED for patients screened with the test, resulting in an estimated savings of $2,235 per sepsis patient for the hospital1.
“We’re honored that Beauregard Health System has chosen to bring IntelliSep to their Emergency Department,” said Ajay Shah, co-founder and CEO of Cytovale. “Investing in advanced diagnostic tools like IntelliSep demonstrates a clear focus on improving patient care for the community they serve. For clinicians working on the frontlines in rural Emergency Departments, having fast, objective information early can help guide care with greater confidence—ensuring patients receive the attention they need as quickly as possible.”For other hospitals and health systems interested in implementing IntelliSep in their ED, please contact info@cytovale.com.
About Cytovale®
Cytovale is committed to improving patient care by pioneering early detection technologies that assess immune activation to accelerate the time it takes to get from triage to life-saving therapies. Cytovale’s U.S. Food and Drug Administration-cleared rapid sepsis diagnostic, IntelliSep®, leverages machine learning and advanced microfluidics to provide Emergency Department clinicians with an objective and highly sensitive early detection tool for sepsis. IntelliSep measures the dysregulated immune system response to infection that would indicate sepsis and generates results in about eight minutes using a standard blood draw. Cytovale is based in San Francisco and venture-backed by Norwest Venture Partners, Sands Capital and Global Health Investment Corporation (GHIC). For more information, visit www.cytovale.com and follow Cytovale on LinkedIn and X.
About Beauregard Health System: Beauregard Health System is dedicated to advancing rural healthcare by providing personalized solutions that improve well-being, promote healing, and inspire hope. As a locally operated, not-for-profit organization, BHS continues to be recognized for excellence as the preferred healthcare provider and community partner.
References:
1AHRQ Report to Congress: An Assessment of Sepsis in the United States and its Burden on Hospital Care (2023)
Assuming average $2,941 cost per inpatient day; $25,000 per sepsis admission and LOS of 8.5 days